GlassScriptPhysician profile
Jacqueline Devita
NPI 1134629553
$4,272.71
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,051 · 2022: $1,592 · 2023: $1,220 · 2024: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,530 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,529.81 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $396.38 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $348.25 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $321.88 | 2022-2024 | Sotyktu |
| Incyte Corporation | $319.93 | 2021-2024 | Opzelura |
| Janssen Biotech, INC. | $294.41 | 2021-2024 | Tremfya, Stelara, Simponi |
| Sun Pharmaceutical Industries INC. | $293.05 | 2021-2024 | Absorica Ld, Winlevi |
| Abbvie INC. | $292.69 | 2021-2023 | |
| Leo Pharma INC. | $272.79 | 2022 | |
| Arcutis Biotherapeutics, INC. | $190.23 | 2023-2024 | Zoryve |
| Lilly USA, LLC | $185.20 | 2021-2024 | Taltz, Olumiant |
| Galderma Laboratories, L.P. | $171.68 | 2021-2024 | Aklief, Oracea, Epsolay |
| Almirall LLC | $168.06 | 2021-2023 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $121.97 | 2021-2024 | Arazlo, Jublia |
| Journey Medical Corporation | $120.66 | 2022 | |
| Genzyme Corporation | $103.38 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $103.21 | 2021 | |
| Epi Health, LLC | $93.51 | 2021 | |
| Amgen INC. | $62.41 | 2021-2023 | Otezla |
| Dermavant Sciences, INC. | $61.72 | 2023 | Vtama |
| Nabriva Therapeutics, Plc | $54.85 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.49 | 2023-2024 | Spevigo |
| Paratek Pharmaceuticals, INC. | $48.08 | 2024 | Nuzyra |
| Mayne Pharma Commercial LLC | $45.38 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $40.50 | 2021-2022 | |
| Merz North America, INC. | $26.96 | 2021 | |
| Verrica Pharmaceuticals INC. | $24.61 | 2023 | Ycanth |
| Sebela Pharmaceuticals INC. | $22.31 | 2021 | |
| Kyowa Kirin, INC. | $18.79 | 2021 | |
| Dermira, INC. | $18.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Devita listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.